Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361686 | 0.78 | NOS2 (0.39) | KDM4EHCRTR1LMNAMAPTELANE | |
| SCHEMBL3967601 | 0.76 | RECQL (0.31) | ALDH1A1 | |
| SCHEMBL14361737 | 0.74 | KDM1A (0.32) | KDM4EHCRTR1LMNAMAPTALDH1A1 | |
| SCHEMBL9469517 | 0.74 | PKM (0.38) | ELANEALDH1A1L3MBTL1 | |
| SCHEMBL3968948 | 0.73 | KDM4E (0.33) | KDM4EHCRTR1LMNAMAPTELANE | |
| SCHEMBL3969714 | 0.73 | MAPT (0.31) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL3970496 | 0.71 | KDM4E (0.33) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL3972771 | 0.71 | KDM4E (0.33) | KDM4EHCRTR1LMNAMAPTL3MBTL1 | |
| SCHEMBL3972388 | 0.71 | KDM4E (0.33) | KDM4EHCRTR1LMNAMAPT | |
| SCHEMBL14361651 | 0.71 | ELANE (0.35) | KDM4EMAPTELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | KDM4E 2397/4885HCRTR1 3355/4885LMNA 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.